Vyome Holdings, Inc.

Vyome Holdings, Inc. is a clinical-stage specialty pharmaceutical company based in Cambridge, MA, Princeton, NJ, and New Delhi, India. The company focuses on treating immune-inflammatory and rare diseases with next-generation therapeutic solutions, leveraging a US-India innovation corridor. On August 15, 2025, the company completed a merger with Vyome Therapeutics, Inc., resulting in the company being renamed "Vyome Holdings, Inc." and Vyome Therapeutics, Inc. continuing as a subsidiary. Vyome Holdings, Inc.'s lead program is VT-1953, a topical gel in development to treat signs and symptoms of malignant fungating wounds in advanced cancer. This program has announced positive results from a phase 2 investigator-initiated trial. The company plans discussions with the Food & Drug Administration (FDA) on a pivotal phase 3 trial design in the first half of 2026. The company also has VT-1908, an ophthalmic drops program in the Pre-Investigational New Drug application stage. This program is a repurposed immune modulator intended to treat steroid-sparing anterior uveitis. Additionally, VB1953, a late clinical-stage program for moderate to severe acne, has completed its Phase II clinical trial and is Phase 3-ready.